Glossary

A Glossary of Stem Cell Terminology

Fifty terms — from autologous to xenogeneic — read in the register the older Cheongdam and Apgujeong consult rooms tend to use.

By Liu Mei-Hua · 2026-05-09

One arrives at the cellular-therapy conversation expecting a single vocabulary, and the Korean corridor — and this matters — does not offer one. The terminology is wider than the marketing copy suggests; the registers sit on different regulatory shelves, address different indications, and depend on different processing arcs. What follows is a categorical glossary of fifty terms a careful patient is likely to encounter in a Cheongdam or Apgujeong consult room, read as the older corridor reads them — the definitions calibrated, the cross-references drawn, the regulatory register articulated where it matters. 先學識個語言，再講療程 — learn the vocabulary first, the protocol after, as the corridor's phrasing has it.

A-Z index

The fifty terms are grouped alphabetically below; the index lets a reader jump to the relevant register. Adipose-derived stem cell · Allogeneic · Apheresis · Autologous · Bone marrow · Cell culture · Cell line · Cell viability · Conditioned media · Contraindication · Cryopreservation · Cytokine · Differentiation · DMSO · Doubling time · Embryonic stem cell · Exosome · Expanded access · Extracellular vesicle · Flow cytometry · GMP · Growth factor · Hematopoietic stem cell · Iliac crest · Immunomodulation · Induced pluripotent stem cell · Indication · Informed consent · Lipoaspirate · Lot number · Manipulation · Mesenchymal stem cell · Minimal manipulation · MFDS · MSC · Off-label · Paracrine signalling · Passage number · Platelet-rich plasma · Pluripotent · Potency assay · Regenerative medicine · Stromal vascular fraction · Subcutaneous · Tissue bank · Umbilical cord · Viability · Wharton's jelly · Xenogeneic · Yield.

A

The four A-terms a patient is likeliest to encounter at the Cheongdam consult — adipose-derived, allogeneic, apheresis, autologous — sit at the centre of the cellular-therapy taxonomy.

Adipose-derived stem cell (ADSC)

A mesenchymal stem cell harvested from the patient's own subcutaneous adipose tissue — most commonly from the periumbilical region or the flank — and either re-administered within the same procedural arc (under the minimal-manipulation register) or cultured under laboratory conditions and expanded across multiple passages before re-administration (under the cellular-therapy register). The ADSC sits at the centre of the autologous Korean corridor; the older Cheongdam practices have absorbed substantial procedural depth on the harvest, the lipoaspirate processing, and the re-administration arc. A patient at consult should expect the harvest to be discussed as a procedural step in its own right — local anaesthesia, donor-site discipline, and the laboratory-processing window articulated honestly. See also: autologous, lipoaspirate, mesenchymal stem cell, stromal vascular fraction.

Allogeneic

Cellular material sourced from a donor rather than from the patient — most commonly, in the Korean regenerative-medicine corridor, umbilical cord tissue or Wharton's jelly drawn under a registered tissue-bank framework. The allogeneic register sits on a meaningfully tighter regulatory footing than the autologous register; donor screening, lot traceability, and adverse-event surveillance are calibrated under the Ministry of Food and Drug Safety's cellular-therapy framework. A patient considering an allogeneic protocol should expect the consult to articulate the source, the donor-screening protocol, and the tissue-bank's regulatory standing. 合異體要分清楚規管 — the allogeneic register requires a clearer regulatory reading. See also: autologous, tissue bank, umbilical cord, Wharton's jelly.

Apheresis

A procedure that withdraws blood from a donor or patient, separates a target cellular population (platelets, leucocytes, or — in the haematopoietic register — peripheral-blood stem cells) under a centrifugation arc, and returns the remaining components to circulation. The term is encountered most often in the haematology and oncology institutional setting rather than in the boutique regenerative-medicine corridor; a patient considering a cellular-therapy protocol in a Cheongdam or Apgujeong consult will rarely encounter the term except as a reference to the wider cellular-therapy taxonomy. The procedural arc is institutional rather than outpatient. See also: hematopoietic stem cell, peripheral blood stem cell.

Autologous

Cellular material drawn from the patient's own tissue — adipose, bone marrow, peripheral blood — and re-administered to the same patient under the relevant procedural arc. The autologous register sits at the centre of the Korean outpatient cellular-therapy corridor; the regulatory framework articulated by the Ministry of Food and Drug Safety treats minimal-manipulation autologous protocols on a meaningfully lighter register than the allogeneic and cultured-and-expanded categories. A patient at consult should expect the autologous framing to be articulated cleanly — donor site, processing arc, re-administration window — and the regulatory register to be distinguished from the allogeneic register where the practice offers both. See also: allogeneic, adipose-derived stem cell, bone marrow, minimal manipulation.

B

The B-terms map to the bone-marrow register — the institutionally older cellular-therapy framework, with its own procedural and regulatory weight.

Bone marrow

The soft, vascular tissue housed within the cancellous bone of the iliac crest, sternum, and proximal long bones — and the source, in the bone-marrow mesenchymal stem cell register, of the cellular yield drawn under iliac-crest aspiration. The bone-marrow register is institutionally older than the adipose register; the published cellular-therapy literature has treated bone-marrow MSC as a reference category for two decades. A patient considering the bone-marrow register should expect the consult to articulate the iliac-crest aspiration arc, the local-anaesthesia or sedation framework, and the orthopaedic-trained clinician's role in the procedural register. The procedural depth is the marker. See also: iliac crest, mesenchymal stem cell, autologous.

C

The C-terms sit at the laboratory's interior — the cellular-expansion arc, the quality-control register, and the patient-facing protocols that translate the laboratory's discipline into the consult-room conversation.

Cell culture

The laboratory protocol under which cellular material is maintained, expanded, and characterised across a controlled environment — temperature, atmosphere, culture-medium composition, and passage discipline — over a defined timeline. The cell-culture register is the laboratory infrastructure that makes the cultured-and-expanded mesenchymal stem cell category possible; the cleaner Korean cellular-manufacturing facilities articulate the culture protocol under quality-management frameworks calibrated to the Ministry of Food and Drug Safety's cellular-therapy register. A patient at consult should expect the practice's culture-protocol framework to be referenced — passage limits, viability criteria, characterisation panel — without the laboratory's discipline being collapsed into a marketing claim. See also: passage number, cell viability, GMP, potency assay.

Cell line

A defined cellular population maintained under continuous culture across multiple passages — characterised, quality-controlled, and (in the registered cellular-therapy register) calibrated to a documented manufacturing protocol. The term is encountered most often in the allogeneic register, where the cellular product is drawn from a registered cell line under tissue-bank or cellular-manufacturing discipline rather than from a patient-side harvest. The cell-line register's appeal — reproducibility across the lot, calibrated cellular characteristics — is balanced by the regulatory discipline the register requires. See also: allogeneic, lot number, tissue bank, GMP.

Cell viability

The proportion of cells in a given preparation that are alive and metabolically active at the point of administration — typically measured under a vital-dye exclusion assay (trypan blue is the longstanding reference) or under flow-cytometric viability-marker analysis. The cleaner Korean cellular-manufacturing facilities articulate viability targets in the patient-facing record; viability above an agreed threshold is part of the lot-release criteria the cultured-and-expanded register sits within. A patient at consult should expect the practice's viability framework to be referenced rather than overstated. See also: flow cytometry, GMP, lot number, potency assay.

Conditioned media

The cell-culture supernatant — the liquid medium drawn off after cellular expansion under controlled culture conditions — carrying the secreted growth factors, cytokines, and extracellular-vesicle population the cellular line releases. Conditioned media sit at the edge of the cellular-therapy taxonomy; the cosmetic-medicine and select regenerative-medicine corridors have read the category as a paracrine-signalling adjunct, and the regulatory standing varies meaningfully across the products on offer. The conservative reading is the adjunct framing — paired with microneedling, with cellular protocols, with aesthetic registers — rather than the standalone-cellular framing some marketing materials suggest. See also: cytokine, exosome, growth factor, paracrine signalling.

Contraindication

A clinical condition or patient-side factor that makes a given cellular-therapy protocol inadvisable or unsafe — active malignancy in the relevant indication-window, uncontrolled coagulopathy, pregnancy, active infection at the donor or recipient site, and the specific contraindications calibrated to the protocol the practice offers. The contraindication conversation is part of the conservative consult's discipline; a practice that does not articulate the contraindication framework cleanly is, in the careful reading, working under thinner clinical discipline than a careful patient should accept. The contraindication register is part of the patient-safety architecture. See also: indication, informed consent.

Cryopreservation

The protocol under which cellular material is stored under controlled freezing conditions — typically in liquid nitrogen vapour at minus-150 degrees Celsius or below — for later use, with a cryoprotectant (most commonly DMSO under a 5 to 10 percent register) added to limit ice-crystal injury during the freezing arc. Cryopreservation underpins the tissue-bank category, the cultured-cellular-product category, and the patient-side cellular banking some Korean practices offer. A patient encountering the cryopreservation register at consult should expect the storage facility, the lot identification, and the post-thaw viability framework to be articulated honestly. See also: cell viability, DMSO, lot number, tissue bank.

Cytokine

A small signalling protein released by cells under physiological or therapeutic stimulus — interleukins, interferons, chemokines, and the wider register the immunology and cellular-therapy literature articulates. The cellular-therapy register reads cytokine signalling as one mechanism through which mesenchymal stem cell protocols may carry their therapeutic register; the paracrine-signalling framing rests on the cytokine and extracellular-vesicle population the cellular product releases. A patient at consult should expect the cytokine register to be discussed honestly rather than as a marketing claim. See also: extracellular vesicle, growth factor, paracrine signalling.

D

The D-terms cover the cellular-line discipline a careful patient encounters at the cleaner cellular-manufacturing register's edge.

Differentiation

The cellular process under which a less-differentiated cell — a stem cell or progenitor — develops into a more-specialised cellular phenotype, calibrated by the cellular environment and the signalling register the cell encounters. Differentiation potential is part of the way the regenerative-medicine literature characterises mesenchymal stem cells; the trilineage differentiation framework (osteogenic, chondrogenic, adipogenic) is one register under which the International Society for Cell and Gene Therapy has framed the MSC category's defining criteria. A patient at consult will rarely encounter the differentiation framework articulated directly, but the cellular characterisation behind the protocol rests on the register. See also: mesenchymal stem cell, pluripotent, potency assay.

DMSO (Dimethyl sulfoxide)

A small organic-solvent molecule used at a 5 to 10 percent concentration register as the cryoprotectant in cellular cryopreservation protocols — the molecule limits ice-crystal injury during the freezing arc and is partially removed during the post-thaw wash before re-administration. DMSO is the longstanding reference cryoprotectant in the cellular-therapy register; some patients report a transient garlic-like taste or odour after re-administration of DMSO-containing cellular preparations, and the cleaner Cheongdam practices articulate the register honestly at consult. The post-thaw protocol is part of the laboratory's discipline. See also: cryopreservation, lot number.

Doubling time

The interval over which a cellular population in culture doubles in cell number under defined conditions — temperature, atmosphere, culture-medium composition, and seeding density. The doubling-time register is one parameter the cellular-manufacturing register tracks across the cellular-expansion arc; deviation from the established doubling-time profile may indicate cellular senescence, contamination, or a shift in the cellular phenotype, and the cleaner cellular-manufacturing facilities calibrate lot-release criteria around the parameter. A patient at consult will rarely encounter the doubling-time register directly, though the laboratory's discipline behind the cultured-and-expanded register sits within it. See also: cell culture, passage number, cell viability.

E

The E-terms sit at the centre of the recently expanded Korean corridor — exosome, extracellular vesicle, and the embryonic and expanded-access registers a careful patient should distinguish.

Embryonic stem cell (ESC)

A pluripotent stem cell derived from the inner cell mass of the early-stage blastocyst — the cellular population the developmental-biology literature has read as the reference for pluripotency. The embryonic stem cell register sits at a meaningfully different regulatory and ethical-review register from the mesenchymal-stem-cell categories the boutique Korean corridor offers; ESC protocols are concentrated in the academic-research register rather than the outpatient regenerative-medicine consult. A patient encountering the term in a Cheongdam consult should read the register carefully — the boutique corridor's outpatient cellular protocols are, in the conservative reading, almost never the embryonic-stem-cell category. See also: induced pluripotent stem cell, pluripotent, mesenchymal stem cell.

Exosome

A small extracellular vesicle (typically 30 to 150 nanometres in diameter) released by cells under physiological or therapeutic stimulus, carrying signalling molecules — proteins, lipids, microRNAs — and read by the cellular-therapy literature, increasingly, as a paracrine-signalling mechanism that may carry part of the therapeutic register cellular protocols deliver. The exosome category has expanded most rapidly in the Korean corridor across the past decade; the regulatory framework articulated by the Ministry of Food and Drug Safety has been more recently calibrated, and the practices that administer exosome protocols vary in how cleanly they articulate the register. The conservative reading is the adjunct framing rather than the standalone-cellular framing. See also: extracellular vesicle, paracrine signalling, conditioned media.

Expanded access

A regulatory framework under which an investigational cellular protocol — one that has not yet completed the routine approval arc — may be made available to a defined patient population outside a clinical-trial register, under documented institutional-review and consent discipline. The expanded-access register exists in the Korean cellular-therapy framework and a foreign patient may, in select institutional settings, encounter the framing. The conservative reading is straightforward: the register is calibrated under a research framework rather than a routine clinical one, and the consent and expected-outcome framing should match the register. See also: indication, informed consent, off-label.

Extracellular vesicle (EV)

A category of cell-derived vesicles released into the extracellular space — encompassing exosomes (the smaller register), microvesicles, and apoptotic bodies — and carrying signalling cargo to recipient cells under the paracrine-signalling framework. The EV category is the broader taxonomic register within which the exosome subset sits; the cellular-therapy literature has read EVs as one mechanism through which cellular protocols may carry their therapeutic register. A patient at consult will more often encounter the exosome term than the wider EV register, though the cleaner practices articulate the taxonomic distinction honestly. See also: exosome, paracrine signalling, conditioned media.

F

The F-term sits at the laboratory's quality-control register — the analytical instrument the cellular-manufacturing facilities use to characterise the cellular product.

Flow cytometry

A laboratory technique that characterises cellular populations by passing them, in a fluid stream, through a laser-illuminated detection register — measuring cell size, granularity, and the surface-marker expression profile under fluorescent-antibody staining. Flow cytometry is the reference characterisation register for mesenchymal stem cells; the International Society for Cell and Gene Therapy's defining MSC criteria include surface-marker expression patterns (CD73, CD90, CD105 positive; CD34, CD45 negative) calibrated under the technique. A patient at consult will rarely encounter the flow-cytometric register directly, though the cellular characterisation behind the cultured-and-expanded category rests on it. See also: cell viability, mesenchymal stem cell, potency assay.

G

The G-terms cover the manufacturing-discipline register and the wider growth-factor framework patients encounter in the cellular-therapy consult.

GMP (Good Manufacturing Practice)

A regulatory framework that calibrates the cellular-manufacturing register — facility design, quality-management system, batch-record discipline, environmental monitoring, and the wider production arc — to standards calibrated under the relevant national regulatory authority. The Korean Ministry of Food and Drug Safety articulates GMP standards for cellular-therapy products under the country's regulatory framework; cleaner Korean cellular-manufacturing facilities operate under GMP discipline, and the cleaner Cheongdam regenerative-medicine practices that work in the cultured-and-expanded register tend to maintain a documented institutional partnership with a GMP-registered facility. The institutional depth is the marker. See also: cell culture, lot number, MFDS, manipulation.

Growth factor

A small protein released by cells that regulates cellular growth, differentiation, and the wider physiological-response register — platelet-derived growth factor, transforming growth factor beta, vascular endothelial growth factor, and the wider register the cellular-biology literature articulates. Growth factors sit at the centre of the platelet-rich plasma register's mechanism, the conditioned-media adjunct register, and the wider paracrine-signalling framework through which mesenchymal stem cell protocols may carry their therapeutic register. A patient at consult should expect the growth-factor register to be discussed honestly rather than as a marketing claim. See also: cytokine, paracrine signalling, platelet-rich plasma.

H

The H-term covers the haematopoietic register — institutionally adjacent to the boutique cellular-therapy corridor but read on a meaningfully different shelf.

Hematopoietic stem cell (HSC)

A multipotent stem cell that gives rise to the wider blood-cell register — red cells, white cells, platelets — under the haematopoietic-differentiation framework, and the cellular population at the centre of bone-marrow transplant and the wider haematology and oncology institutional setting. The HSC register sits in tertiary-hospital haematology and oncology rather than the boutique outpatient regenerative-medicine corridor; the indication scope encompasses haematological-malignancy treatment registers and select bone-marrow-failure presentations. A foreign patient researching cellular therapy in Korea may encounter the term — and may find it referenced loosely in the corridor's marketing — and the categorical distinction is part of what a careful patient should read. See also: bone marrow, mesenchymal stem cell, apheresis.

I

The I-terms cover the procedural register at the bone-marrow harvest, the immunological framework, the iPSC category, and the patient-facing indication and consent discipline.

Iliac crest

The upper, curved border of the ilium — the largest of the three bones forming the pelvis — and the standard donor site for autologous bone-marrow aspiration in the orthopaedic and regenerative-medicine register. The iliac-crest aspiration arc is, in the conservative reading, a more demanding procedural step than the adipose harvest; the practices that work in the bone-marrow MSC register tend to have absorbed the orthopaedic-specialist depth that the procedure requires. A patient at consult should expect the iliac-crest aspiration to be discussed as a procedural step in its own right — local anaesthesia or sedation framework, donor-site discipline, the cellular-yield expectation. See also: bone marrow, mesenchymal stem cell, autologous.

Immunomodulation

The capacity of certain cellular populations — mesenchymal stem cells in particular — to modulate the host's immune-response register under a paracrine-signalling and cell-contact framework. The immunomodulatory register is one of the mechanisms through which the cellular-therapy literature has read the MSC category's therapeutic potential; the framework underpins the indication scope the regenerative-medicine corridor articulates for select inflammatory and autoimmune presentations. A patient at consult should expect the immunomodulatory register to be discussed honestly rather than expanded into a wider therapeutic claim. See also: cytokine, mesenchymal stem cell, paracrine signalling.

Induced pluripotent stem cell (iPSC)

A pluripotent stem cell derived by reprogramming a differentiated somatic cell — most commonly a fibroblast or peripheral-blood mononuclear cell — through the introduction of defined transcription factors. The iPSC category sits at the centre of the contemporary regenerative-medicine research-protocol register and is concentrated in the academic-research setting rather than the boutique outpatient corridor. A foreign patient encountering the term in a Cheongdam consult should read the register carefully — iPSC protocols, in the conservative reading, are almost never the boutique outpatient cellular protocol the consult is articulating. See also: embryonic stem cell, pluripotent, expanded access.

Indication

The clinical condition for which a given cellular-therapy protocol is approved, registered, or — in select registers — administered under the relevant clinical framework. The indication conversation is part of the conservative consult's discipline; a practice that does not articulate the indication scope cleanly, or that expands the cellular protocol's indication register beyond the published evidence base, is working under thinner clinical discipline than a careful patient should accept. A patient at consult should expect the indication match between presentation and protocol to be discussed honestly. See also: contraindication, off-label, informed consent.

L

The L-terms cover the lipoaspirate harvest and the lot-discipline register at the cellular-manufacturing facility's interior.

Lipoaspirate

The adipose-tissue and tumescent-fluid mixture drawn under low-pressure liposuction from a defined donor site — most commonly the periumbilical region or the flank — and the source material for the autologous adipose-derived stem cell register and the stromal vascular fraction category. The lipoaspirate processing arc is part of the laboratory discipline behind the cultured-and-expanded ADSC register and the same-day SVF register; the cleaner practices articulate the harvest, the donor-site discipline, and the processing window honestly at consult. See also: adipose-derived stem cell, stromal vascular fraction, subcutaneous.

Lot number

A unique identifier assigned to a defined batch of cellular product — autologous, allogeneic, or cultured-and-expanded — under the cellular-manufacturing register's batch-record discipline. The lot-number register underpins traceability, post-administration adverse-event surveillance, and the institutional-quality framework the cleaner practices articulate. A patient receiving a cultured-and-expanded or allogeneic cellular product should expect the lot identification to be documented in the patient-facing record; the documentation is part of the patient-safety architecture. See also: cell viability, GMP, MFDS, tissue bank.

M

The M-terms — manipulation, mesenchymal stem cell, MFDS, MSC, minimal manipulation — sit at the regulatory and taxonomic centre of the Korean cellular-therapy corridor.

Manipulation

The processing register applied to cellular material between harvest and re-administration — washing, centrifugation, enzymatic digestion, cellular expansion, characterisation. The manipulation register is the regulatory variable that distinguishes the minimal-manipulation autologous protocols from the cultured-and-expanded cellular-therapy register; the Ministry of Food and Drug Safety calibrates the regulatory framework around the manipulation arc the cellular product has undergone. A patient at consult should expect the manipulation register to be articulated honestly — a cultured-and-expanded protocol is not, in the conservative reading, a minimal-manipulation protocol. See also: minimal manipulation, GMP, MFDS, cell culture.

Mesenchymal stem cell (MSC)

A multipotent stromal cell with capacity to differentiate along osteogenic, chondrogenic, and adipogenic lineages under defined induction conditions, characterised under surface-marker expression patterns the International Society for Cell and Gene Therapy has framed (CD73, CD90, CD105 positive; CD34, CD45 negative). The MSC category sits at the centre of the regenerative-medicine cellular-therapy literature; the autologous adipose-derived, autologous bone-marrow, and allogeneic umbilical cord registers all sit within the wider MSC framework. A patient at consult should expect the MSC register's defining characteristics to be articulated honestly rather than collapsed into a marketing claim. See also: differentiation, flow cytometry, multipotent.

MFDS (Ministry of Food and Drug Safety)

The Korean regulatory authority that calibrates the cellular-therapy framework — the cellular-product approval register, the cellular-manufacturing GMP discipline, the post-marketing adverse-event surveillance, and the wider regulatory architecture under which the Korean corridor operates. The Korean MFDS framework calibrates the cellular-therapy register on a meaningfully tighter footing than some adjacent markets articulate, and the cleaner Cheongdam practices reference the framework honestly at consult. A patient researching the corridor should expect the MFDS register to be referenced where it matters — manipulation classification, lot identification, regulatory standing of the specific cellular product. See also: GMP, manipulation, minimal manipulation, regenerative medicine.

Minimal manipulation

A regulatory framing under which cellular material is processed without cellular expansion, without alteration of the cellular characteristics relevant to the intended use, and within a same-day or closely-sequenced procedural arc. The minimal-manipulation register is the framework under which most autologous adipose and SVF protocols sit in the Korean cellular-therapy corridor; the regulatory register is meaningfully lighter than the cultured-and-expanded category, though the procedural and clinical discipline remain calibrated. A patient at consult should expect the minimal-manipulation framing to be articulated honestly — a cultured protocol is not, by definition, a minimal-manipulation protocol. See also: manipulation, MFDS, stromal vascular fraction, cell culture.

MSC (see Mesenchymal stem cell)

The acronym MSC, used routinely in the cellular-therapy literature and in the patient-facing record at the cleaner Cheongdam practices, refers to the mesenchymal stem cell category — the multipotent stromal cell at the centre of the autologous adipose-derived, autologous bone-marrow, and allogeneic umbilical cord cellular-therapy registers. A patient encountering the acronym at consult should expect the underlying cellular characterisation, the manipulation register, and the indication scope to be articulated honestly rather than collapsed into the acronym alone. See also: mesenchymal stem cell, differentiation, multipotent.

O

The O-term sits at the regulatory edge — the off-label register a careful patient should distinguish from the routine clinical framework.

Off-label

The administration of an approved cellular product or pharmaceutical for an indication outside the regulatory-approved scope — under the prescribing clinician's discretion and within the relevant clinical framework. The off-label register exists across cellular therapy and pharmaceutical practice; the conservative reading is that off-label administration should be discussed openly at consult, with the indication match, the published evidence base, and the patient's expected-outcome framing calibrated to the register. A practice that administers a cellular product outside its approved indication scope without articulating the off-label framing is, in the careful reading, working under thinner regulatory discipline than a careful patient should accept. See also: indication, expanded access, informed consent.

P

The P-terms cover the laboratory's passage discipline, the platelet-rich plasma adjunct register, the paracrine-signalling framework, the pluripotency taxonomy, and the potency-assay register.

Paracrine signalling

The cellular-communication register through which cells release signalling molecules — cytokines, growth factors, extracellular vesicles — that act on neighbouring cells in the local microenvironment, distinct from the autocrine register (the cell signalling itself) and the endocrine register (long-distance circulation-borne signalling). The paracrine register is one of the central frameworks through which the cellular-therapy literature has read the MSC category's therapeutic register; the cellular-product mechanism may rest more substantively on the paracrine register than on the cellular engraftment some early framings emphasised. A patient at consult should expect the framing to be articulated honestly. See also: cytokine, exosome, growth factor, immunomodulation.

Passage number

The number of times a cellular population in culture has been subcultured — moved into fresh culture medium and a new culture vessel — across the cellular-expansion arc. The passage-number register is a quality-control parameter the cellular-manufacturing facilities track; cellular populations carried across too many passages may show senescence, altered surface-marker profile, or shifted differentiation potential, and the cleaner manufacturing facilities calibrate lot-release passage limits accordingly. A patient at consult will rarely encounter the passage-number register directly, though the laboratory's discipline behind the cultured-and-expanded register sits within it. See also: cell culture, doubling time, GMP, mesenchymal stem cell.

Platelet-rich plasma (PRP)

A blood-derived preparation in which platelets have been concentrated above the baseline whole-blood register — typically through centrifugation of a peripheral-blood draw — and re-administered to the patient under the relevant procedural arc. PRP is, strictly read, not a cellular therapy in the strict sense — the active components are platelets and the growth factors they release, not stem cells — but the conservative Korean practices include PRP in the regenerative-medicine taxonomy because it sits on the same procedural shelf, addresses overlapping indications, and is frequently administered in adjunct registers with cellular protocols. The conservative reading is the adjunct framing rather than the substitute framing. See also: growth factor, regenerative medicine, paracrine signalling.

Pluripotent

A cellular-potency framing under which the cell is capable of differentiating into cell types representing all three embryonic germ layers — endoderm, mesoderm, and ectoderm. Pluripotency is the defining cellular register of the embryonic stem cell and induced pluripotent stem cell categories; mesenchymal stem cells, by contrast, sit on the multipotent register — capable of differentiating along a defined lineage panel rather than across all three germ layers. The taxonomic distinction matters; a patient encountering the pluripotent framing in a boutique outpatient consult should read the register carefully. See also: embryonic stem cell, induced pluripotent stem cell, mesenchymal stem cell.

Potency assay

A laboratory test that measures the biological activity of a cellular product against a defined functional register — differentiation capacity, immunomodulatory activity, cytokine-release profile, or another mechanism-of-action-relevant parameter. The potency-assay register is part of the lot-release discipline at the cleaner cellular-manufacturing facilities; potency above an agreed threshold is part of the cellular product's release criteria. A patient at consult will rarely encounter the potency-assay register directly, though the laboratory's discipline behind the cultured-and-expanded register sits within it. See also: cell viability, flow cytometry, GMP, MSC.

R

The R-term covers the wider taxonomic register the cellular-therapy categories sit within.

Regenerative medicine

The wider clinical and scientific register that encompasses cellular therapy, gene therapy, tissue engineering, and adjacent approaches calibrated to the restoration of tissue or organ function under a biological-mechanism framework. The regenerative-medicine register is the taxonomic shelf on which the autologous adipose-derived, autologous bone-marrow, allogeneic umbilical cord, exosome, conditioned-media, and PRP registers all sit. A patient at consult should expect the wider taxonomic framework to be articulated honestly — the cellular-therapy register is one register within the wider regenerative-medicine framework rather than the framework's totality. See also: cellular therapy, mesenchymal stem cell, platelet-rich plasma.

S

The S-terms cover the stromal vascular fraction register and the subcutaneous donor-site discipline at the autologous adipose harvest.

Stromal vascular fraction (SVF)

The heterogeneous cellular population isolated from the adipose-tissue stromal compartment under enzymatic digestion or mechanical processing of the lipoaspirate — comprising mesenchymal stem cells, endothelial precursor cells, pericytes, and a wider register of cellular and extracellular components. The SVF register sits within the minimal-manipulation autologous framework; the procedural appeal — same-day administration, no cellular-expansion laboratory step — is balanced by a more variable cellular composition than the cultured registers deliver. The taxonomic distinction between SVF and cultured ADSC is part of the way a careful patient should read the consult conversation. See also: adipose-derived stem cell, lipoaspirate, mesenchymal stem cell, minimal manipulation.

Subcutaneous

The anatomical layer between the skin (the cutaneous register) and the underlying muscle and fascia — the layer in which adipose tissue is housed and the donor site for the autologous adipose-derived stem cell harvest. The subcutaneous donor-site discipline is part of the procedural register at the cleaner Cheongdam practices; the periumbilical region and the flank are the standard donor sites, and the local-anaesthesia framework, the harvest volume, and the donor-site recovery arc are calibrated to the procedural register. A patient at consult should expect the donor-site conversation to be articulated honestly. See also: adipose-derived stem cell, lipoaspirate, autologous.

T

The T-term sits at the institutional centre of the allogeneic cellular-therapy register — the tissue-bank framework under which donor-derived cellular products are processed and made available.

Tissue bank

An institutionally registered facility that collects, processes, stores, and distributes human tissue or cellular products under regulatory discipline calibrated to the relevant national framework — donor screening, lot identification, processing-chain documentation, and adverse-event surveillance. The tissue-bank register sits at the centre of the allogeneic umbilical cord cellular-therapy category; the cleaner Cheongdam practices that administer allogeneic protocols tend to do so under a documented institutional partnership with a tissue-bank facility registered under the Korean cellular-therapy framework. The institutional partnership is part of the marker. See also: allogeneic, lot number, MFDS, umbilical cord.

U

The U-term covers the donor-tissue source at the centre of the allogeneic cellular-therapy register a foreign patient is most likely to encounter in the corridor.

Umbilical cord

The connecting structure between the foetus and the placenta, comprising two umbilical arteries, one umbilical vein, and a connective-tissue matrix (Wharton's jelly) — and the donor-tissue source at the centre of the allogeneic cellular-therapy register the boutique Korean corridor most often offers. Umbilical-cord-derived mesenchymal stem cells are sourced under a tissue-bank framework with documented donor screening and lot traceability; the cellular characteristics — younger donor source, calibrated cellular profile, reproducibility across the lot — sit on a meaningfully different register from the autologous adipose and bone-marrow categories. A patient at consult should expect the source, the donor-screening framework, and the tissue-bank's regulatory standing to be articulated honestly. See also: allogeneic, tissue bank, Wharton's jelly, mesenchymal stem cell.

V

The V-term cross-references the cellular-viability register a patient encounters at the laboratory's lot-release framework.

Viability (see Cell viability)

The viability register, in the cellular-therapy framework, refers to the proportion of cells in a given preparation that are alive and metabolically active at the point of administration — the parameter measured under vital-dye exclusion or flow-cytometric viability-marker analysis, and the parameter that sits at the centre of the cellular-manufacturing lot-release framework. A patient receiving a cultured-and-expanded or cryopreserved cellular product should expect viability to be referenced in the patient-facing record. See also: cell viability, cryopreservation, flow cytometry, GMP.

W

The W-term covers the connective-tissue matrix at the centre of the umbilical-cord allogeneic register.

Wharton's jelly

The gelatinous connective-tissue matrix that surrounds the umbilical-cord vessels — comprising a mucopolysaccharide-rich extracellular-matrix framework and a defined cellular population that includes mesenchymal stem cells with a reproducible characterisation profile. Wharton's-jelly-derived MSCs are one source within the wider umbilical cord category; the donor-tissue source, the processing arc, and the tissue-bank's regulatory standing are part of the consult-room conversation a patient should expect at the cleaner Cheongdam practices. The cellular characteristics — younger donor source, calibrated proliferation profile — are part of the category's appeal. See also: umbilical cord, allogeneic, mesenchymal stem cell, tissue bank.

X

The X-term covers the cross-species register — the regulatory and clinical framework patients should distinguish from the human-allogeneic register.

Xenogeneic

Cellular material sourced from a donor of a different species from the recipient — the framework distinct from the allogeneic register (same-species, different donor) and the autologous register (same patient). Xenogeneic cellular protocols sit at the academic-research register in the human-medicine context; the framework is not the routine cellular-therapy register a foreign patient is likely to encounter in the boutique outpatient corridor. The term is included in the glossary because patients researching cellular therapy may encounter it in the wider literature; the categorical distinction matters, and a Cheongdam consult should not, in the conservative reading, articulate a xenogeneic framing in the routine patient-care register. See also: allogeneic, autologous, expanded access.

Y

The Y-term covers the cellular-yield register at the harvest and the cellular-manufacturing framework's interior.

Yield

The cellular quantity produced under a defined harvest, processing, or cellular-expansion arc — measured in cell number, cell number per unit donor tissue, or cell number per unit culture volume, calibrated to the protocol the practice operates under. The yield register is part of the cellular-manufacturing framework; the cleaner facilities articulate yield expectations honestly, and the conservative consult-room reading frames yield realistically rather than over-specifying the parameter for marketing effect. A patient at consult should expect the yield framework to be referenced where it matters — the harvest discussion, the cellular-expansion arc, the lot-release register. 誠實講解產量 — yield should be discussed honestly. See also: cell viability, cell culture, doubling time, lot number.